Director Peter Greenleaf disclosed the sale of 797 shares of Pelthos Therapeutics Inc. common stock (NASDAQ: PTHS) on April 2, 2026, via a Form 4 filed with the Securities and Exchange Commission. The transactions were carried out under a pre-established 10b5-1 trading plan and generated proceeds of $16,669 in total.
The divestiture was split into two trades. The first transaction moved 420 shares at a weighted average price of $20.5151, with execution prices spanning $20.30 to $20.78. The second involved 377 shares at a weighted average price of $21.3614, with prices ranging from $21.31 to $22.03. After these sales, Greenleaf directly holds 24,681 shares of Pelthos Therapeutics.
Following the trades, the stock has traded higher and most recently reached $24.38, although it remains nearly 3% lower on a one-week basis. Analysis on InvestingPro indicates that Pelthos shares appear overvalued compared with that platform's Fair Value assessment.
Alongside the insider activity, Pelthos released financial results that paint a mixed picture for the company. For the fourth quarter of 2025, Pelthos reported an earnings per share of -6.87, which missed consensus expectations of -0.54. Despite the earnings shortfall, the company recorded a 28% sequential increase in revenue, with quarterly sales of $9.1 million.
Pelthos also reported net product revenue of $16.2 million for the full year 2025, a figure tied to the mid-year commercial introduction of its drug. Broker Oppenheimer adjusted its price target modestly to $62 from $60 while keeping an Outperform rating, citing the company’s progress related to the ZELSUVMI rollout.
On the development front, Pelthos announced that the first patient has been dosed in a Phase 1b/2a clinical trial for CT2000, an investigational therapy aimed at treating eye pain. That trial is being executed by Channel Pharmaceutical Corporation, a Pelthos subsidiary. Together, these items reflect the company’s ongoing operational, commercial, and clinical activities.
The disclosed insider sale, the financial results that mixed revenue growth with an EPS miss, and the continued clinical progress together form the immediate factual landscape for Pelthos. Market participants may weigh the director's sale alongside the company’s recent performance and valuation assessments.